Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes
| Autor: | Timothy W. Jones, Luke M. Carroll, Andrzej S. Januszewski, Elizabeth A. Davis, Alicia J. Jenkins, Mugdha V. Joglekar, Emma S. Scott, Gregory R. Fulcher, Anandwardhan A. Hardikar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Adolescent Science Injections Subcutaneous Gastroenterology Article Internal medicine Diabetes mellitus microRNA medicine Humans Hypoglycemic Agents Insulin Child Type 1 diabetes Multidisciplinary business.industry Diabetes diagnosis Diabetes medicine.disease Subcutaneous insulin MicroRNAs Diabetes Mellitus Type 1 Gene Expression Regulation Medicine Female business |
| Zdroj: | Scientific Reports Scientific Reports, Vol 11, Iss 1, Pp 1-4 (2021) |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-021-95824-8 |
| Popis: | To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink